Cardiovascular implications of anti-angiogenic therapeutic agents in cancer patients.

Competing Interests: LA has no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. GKA declares research support from Agenus, Arcus, Astra Zeneca, BioNtech, BMS, Elicio, Genentech/Roche, Helsinn, Parker Institute, Pertzye, Puma, QED, Servier, Yiviva, and consulting support from Abbvie, Astra Zeneca, Autem, Berry Genomics, BioNtech, Boehringer Ingelheim, BMS, Eisai, Exelixis, Genentech/Roche, Incyte, Ipsen, J-Pharma, Merck, Merus, Neogene, Novartis, Servier, Tempus, Vector, Yiviva.